Trial Profile
A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Itraconazole (Primary) ; Pulrodemstat (Primary) ; Rifampicin (Primary)
- Indications Marginal zone B-cell lymphoma; Neuroendocrine carcinoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Celgene Corporation
- 07 Dec 2023 Planned End Date changed from 29 Jun 2025 to 18 Sep 2025.
- 07 Dec 2023 Planned primary completion date changed from 8 Aug 2023 to 18 Sep 2025.
- 16 Sep 2022 Status changed from recruiting to active, no longer recruiting.